Median progression-free survival of six to seven months defines the ceiling that current standard-of-care regimens have repeatedly failed to break in CLDN18.2-positive, HER2-negative advanced gastric cancer, and that stubborn number is precisely why Astellas is now moving a mechanistically distinct weapon into Phase 3. The company dosed the first patient in its pivotal study of ASP2138, a subcutaneously delivered bispecific antibody that simultaneously engages CLDN18.2 on tumor cells and CD3-positive T cells, redirecting immune killing machinery directly to the tumor surface. The trial layers ASP2138 on top of chemotherapy and pembrolizumab, stacking a T-cell engager onto a combination already validated by the KEYNOTE-859 data that underpinned pembrolizumab’s approval in this setting.

The study design is ambitious: 570 participants, randomized, double-blind, placebo-controlled, with co-primary endpoints of overall survival and progression-free survival. The comparator arm is placebo plus chemotherapy with or without pembrolizumab, a flexible control that should accommodate real-world prescribing patterns across multiple countries. What makes the trial genuinely consequential is its position inside a crowded but still evolving target class. Zolbetuximab (Vyloy), Astellas’ own approved CLDN18.2-targeting antibody, already demonstrated first-line benefit in the same biomarker-selected population. ASP2138 operates through an entirely different mechanism, engaging T cells rather than relying on antibody-dependent cellular cytotoxicity, which means Astellas is effectively running a franchise strategy: anchoring the target, then layering mechanistic diversity on top of it.

The subcutaneous delivery route deserves attention beyond convenience. Bispecific T-cell engagers in oncology have historically been administered intravenously, with cytokine release syndrome management complicating outpatient use. A subcutaneous format, if the safety profile from earlier-phase work holds at scale, changes the administration calculus for community oncology settings where gastric cancer patients are frequently treated. That distinction will matter to investigators and payers evaluating the full cost of care, not just efficacy deltas.

Astellas has framed this Phase 3 initiation as part of a corporate commitment to launch five or more Phase 3 or pivotal studies by fiscal year 2027, so ASP2138 is carrying both scientific and portfolio-level weight simultaneously. The number to track from here is the progression-free survival readout: if ASP2138 plus pembrolizumab plus chemotherapy breaks meaningfully past that six-to-seven month floor established by pembrolizumab-based regimens alone, the T-cell engager mechanism earns its franchise credentials. If it merely matches, the differentiation story collapses.

Source link: https://www.prnewswire.com/news-releases/astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-302858691.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.